ENDRA Life Sciences Inc.
NDRA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $4,095 | $2,517 | $2,286 | $3,361 |
| - Cash | $794 | $1,809 | $2,065 | $3,229 |
| + Debt | $525 | $557 | $587 | $584 |
| Enterprise Value | $3,827 | $1,266 | $809 | $716 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$39 | -$33 | -$46 | -$46 |
| % Margin | – | – | – | – |
| EBITDA | -$1,557 | -$1,193 | -$991 | -$4,103 |
| % Margin | – | – | – | – |
| Net Income | -$1,596 | -$1,226 | -$1,036 | -$4,149 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.1 | -1.71 | -1.86 | -7.73 |
| % Growth | -22.8% | 8.1% | 75.9% | – |
| Operating Cash Flow | -$1,164 | -$1,114 | -$1,293 | -$1,516 |
| Capital Expenditures | $0 | $0 | -$17 | $0 |
| Free Cash Flow | -$1,164 | -$1,114 | -$1,310 | -$1,516 |